You are here

Dupixent

Sanofi and Regeneron's medical congress campaign focuses on type 2 inflammation education for docs

Sanofi and Regeneron's medical congress campaign focuses on type 2 inflammation education for docs

Fierce Pharma

Flag link:

Regeneron profit beats expectations on Eylea, Dupixent strength

Regeneron profit beats expectations on Eylea, Dupixent strength

Yahoo/Reuters

Flag link:

Dupixent's already a blockbuster, but there's much more to come: Sanofi exec

Dupixent's already a blockbuster, but there's much more to come: Sanofi exec

Fierce Pharma

atopic dermatitis

Flag link:

Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos

Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos

Fierce Biotech

atopic dermatitis

Flag link:

Pfizer posts detailed phase 3 data on its Dupixent rival

Pfizer posts detailed phase 3 data on its Dupixent rival

Fierce Biotech

clinical trials

atopic dermatitis

Flag link:

Dupixent brings long-awaited profits to Sanofi, Regeneron partnership

Dupixent brings long-awaited profits to Sanofi, Regeneron partnership

BioPharma Dive

Flag link:

Sanofi ups revenues forecasts as eczema drug Dupixent surges

Sanofi ups revenues forecasts as eczema drug Dupixent surges

Pharmaforum

Flag link:

Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps

Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps

Fierce Pharma

Flag link:

FDA Action Alert: Regeneron, Sanofi, Celgene

FDA Action Alert: Regeneron, Sanofi, Celgene

BioSpace

Acer Therapeutics

Dova Pharmaceuticals

Nabriva Therapeutics

Flag link:

Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Stat

monoclonal antibodies

Flag link:

Go or no go? Merck, Regeneron and Alexion await US expansion

Go or no go? Merck, Regeneron and Alexion await US expansion

EP Vantage

Dova Pharmaceuticals

Flag link:

FDA approves Dupixent for atopic dermatitis in adolescents

FDA approves Dupixent for atopic dermatitis in adolescents

BioCentury

atopic dermatitis

Flag link:

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Pharmaforum

clinical trials

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent

Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent

Endpoints

atopic dermatitis

Flag link:

Sanofi drug Dupixent wins U.S. FDA approval to treat asthma

Sanofi drug Dupixent wins U.S. FDA approval to treat asthma

Yahoo/Reuters

Flag link:

Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

Endpoints

Flag link:

Sanofi unveils eczema drug data, as regulators mull label expansion

Sanofi unveils eczema drug data, as regulators mull label expansion

Pharmaforum

atopic dermatitis

Flag link:

Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

Endpoints

Flag link:

Pages